Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | BAD | Q92934 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | NQO1 | P15559 | 3/20 | 0.35 |
| ▸ | CTRC | Q99895 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1535927 | 0.77 | BCL2L1 (0.50) | BCL2L1BAD | |
| SCHEMBL835826 | 0.76 | BCL2L1 (0.43) | BCL2L1BADPARP1NQO1CTRC | |
| SCHEMBL2046938 | 0.74 | BCL2L1 (0.42) | BCL2L1BADPARP1NQO1CTRC | |
| SCHEMBL834706 | 0.74 | PNMT (0.43) | BCL2L1BADPARP1NQO1CTRC | |
| SCHEMBL11317199 | 0.74 | BCL2L1 (0.47) | BCL2L1BADPARP1NQO1GRIA1 | |
| SCHEMBL24133294 | 0.74 | BCL2L1 (0.42) | BCL2L1BADPARP1NQO1CTRC | |
| SCHEMBL3797823 | 0.73 | BCL2L1 (0.56) | BCL2L1BADNQO1CTRCGRIA1 | |
| SCHEMBL1046490 | 0.73 | BCL2L1 (0.50) | BCL2L1BADPARP1NQO1CTRC | |
| SCHEMBL23944932 | 0.72 | PARP1 (0.46) | BCL2L1BADPARP1ALDH1A1NOS3 | |
| SCHEMBL3990034 | 0.72 | MAOA (0.44) | PARP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| WO-2024188994-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-09-19 | — | — | WO | disclosed |
| US-7230031-B2 | Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-12 | — | — | US | disclosed |
| US-20050085541-A1 | Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1471049-A1 | NOVEL THYROID HORMONE RECEPTOR LIGAND, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | NLRP3, NOD1, NLRP1 | BCL2L1 762/4885BAD 338/4885PARP1 376/4885 |
| US-20050085541-A1 | Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof | TSHR, THRA, THRB | BCL2L1 2653/4885BAD 3570/4885PARP1 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.